These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15017601)

  • 1. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis.
    Fontana RJ; Everson GT; Tuteja S; Vargas HE; Shiffman ML
    Clin Gastroenterol Hepatol; 2004 Mar; 2(3):183-97. PubMed ID: 15017601
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C.
    Arthur MJ
    Gastroenterology; 2002 May; 122(5):1525-8. PubMed ID: 11984538
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of chronic Hepatitis C in 2008].
    Niederau C; Kaden T
    MMW Fortschr Med; 2008 Mar; 150(13):31-4. PubMed ID: 18522354
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversal of cirrhosis: evidence-based medicine?
    Desmet VJ; Roskams T
    Gastroenterology; 2003 Aug; 125(2):629-30; author reply 630-31. PubMed ID: 12891578
    [No Abstract]   [Full Text] [Related]  

  • 5. Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
    Hrachovec J; Patel P
    Gastroenterology; 2003 Jun; 124(7):2003-4; author reply 2004-5. PubMed ID: 12812198
    [No Abstract]   [Full Text] [Related]  

  • 6. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
    de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
    J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    Shoeb D; Dearden J; Weatherall A; Bargery C; Moreea S; Alam S; White E; Vila X; Freshwater D; Ryder S; Mills PR; Alexander GJ; Forton D; Foster GR
    J Hepatol; 2014 Apr; 60(4):699-705. PubMed ID: 24291239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral therapy for chronic hepatitis C.
    Sievert W
    Aust Fam Physician; 2003 Oct; 32(10):826-32. PubMed ID: 14596080
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effectiveness of long-acting interferon (peginterferon)].
    Kondo Y; Tateishi R; Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):515-8. PubMed ID: 15359853
    [No Abstract]   [Full Text] [Related]  

  • 10. [New therapeutic agents for chronic hepatitis C].
    Hiramatsu N; Hayashi N
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):170-7. PubMed ID: 14968593
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
    Martínez-Bauer E; Forns X
    Gastroenterol Hepatol; 2003 May; 26(5):303-6. PubMed ID: 12732104
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
    Poynard T; McHutchison J; Manns M; Trepo C; Lindsay K; Goodman Z; Ling MH; Albrecht J
    Gastroenterology; 2002 May; 122(5):1303-13. PubMed ID: 11984517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis C in patients with decompensated cirrhosis.
    Everson GT
    Rev Gastroenterol Disord; 2004; 4 Suppl 1():S31-8. PubMed ID: 15184823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New strategies for treatment of chronic hepatitis C].
    Rizzetto M
    Forum (Genova); 1999; 9(2 Suppl):1-11. PubMed ID: 11300125
    [No Abstract]   [Full Text] [Related]  

  • 15. Progress on the treatment of hepatitis C.
    Nierengarten MB
    Lancet Infect Dis; 2003 Dec; 3(12):748. PubMed ID: 14664249
    [No Abstract]   [Full Text] [Related]  

  • 16. Nonresponse to interferon monotherapy in HCV-related chronic hepatitis: results of retreatment and prognostic factors.
    Capra F; De Maria E; Franchini M; Marchiori L; Thalheimer U; Vantini I
    Dig Dis Sci; 2003 Apr; 48(4):809-14. PubMed ID: 12741476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of obesity on treatment of chronic hepatitis C.
    Charlton MR; Pockros PJ; Harrison SA
    Hepatology; 2006 Jun; 43(6):1177-86. PubMed ID: 16729327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis.
    Shouval D
    J Hepatol; 2012 Feb; 56(2):303-4. PubMed ID: 22015961
    [No Abstract]   [Full Text] [Related]  

  • 20. Interferon + ribavirin combination therapy. Open new approach to treatment of patients with hepatitis C virus.
    Iino S
    Ital J Gastroenterol Hepatol; 1999 Apr; 31(3):216-7. PubMed ID: 10379483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.